An American pharmaceutical Concert Pharmaceuticals Inc. made the official announcement of the results of his latest clinical experimentin the quest to develop a drug to combat alopecia areata.
The drug in development, CTP-543, has shown favorable results in 41.5% of individuals who took doses of 12 milligrams twice a day for 24 weeks. During the period they underwent this experimental treatment they had a increase your scalp by 80%.
“Today marks an important milestone in advancing new treatments for alopecia areata. I am very happy to see such positive results from the first phase 3 trial with CTP-543,” said Brett King, clinical investigator for THRIVE-AA1, in an official statement.
What did the clinical trial consist of?
Concert Pharmaceuticals Inc. conducted a study of 706 adults from the USA, Canada and the United Kingdom between the ages of 18 and 65 who had alopecia. The 706 individuals were divided into 3 groups: one took a placebo, another took an 8-milligram dose twice a day, and the last took a pill of 12 milligrams twice a day.
The fundamental requirement for enrollment in the experiment was to present at least 50% hair loss basing this on the Salt score, which measures the amount of missing hair on a scale of 0 to 100, with 0 being complete preservation of the hair and 100 being total hair loss.
Incredible results.
The group of people who took the 12-milligram dose reached a Salt score of 20, that is, they were able to recover 80% of their total hair. For the group that consumed the dose of 8 milligrams, they obtained a recovery of 29.6% and, finally, those who were treated with placebo, recovered 0.8%.
“With these compelling phase 3 data, we believe that CTP-543 has the potential to be a best-in-class treatment for patients with alopecia areata, a disease that has been largely ignored. We are extremely appreciative of the patients and teams of clinical research professionals involved in our trials,” said James V. Cassella, director of development for Concert Pharmaceuticals.
We recommend you read:
In view of the results obtained, the company has already started sending its findings to scientific publications to later collect them and form the basis of an application for approval of a new drug by the Food and Drug Administration (FDA) in the first half of 2023.
#Alopecia #present #FDA #pill #hair #loss #surprising #results